FAODs Market to Reach $14.68B by 2030 at 7.5% CAGR
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Fatty Acid Oxidation Disorders (FAODs) Market Expected To Change From 2026 To 2030?
The market for fatty acid oxidation disorders (faods) has demonstrated substantial growth in recent years. Its value is anticipated to rise from $10.23 billion in 2025 to $11.01 billion in 2026, advancing at a compound annual growth rate (CAGR) of 7.6%. This historical expansion can be attributed to the implementation of neonatal screening initiatives, an increase in the diagnosis of inherited metabolic disorders, enhanced clinical awareness, the expansion of hospital-based metabolic clinics, and the availability of supportive drug therapies.
The market for fatty acid oxidation disorders (FAODs) is anticipated to experience significant expansion in the coming years. This market is projected to reach $14.69 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.5%. Key factors driving this growth during the forecast period include advances in enzyme replacement therapies, the expansion of genetic research, the rise of personalized nutrition plans, enhanced reimbursement policies for rare diseases, and greater government backing for early screening initiatives. Significant trends expected in the forecast period encompass the increasing adoption of newborn screening programs, a heightened emphasis on the early diagnosis of metabolic disorders, the expanding application of nutritional and dietary management, a broader awareness of rare disease treatments, and improved accessibility to therapies for metabolic disorders.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Factors Are Influencing The Growth Of The Fatty Acid Oxidation Disorders (FAODs) Market?
The fatty acid oxidation disorders (FAODs) market is anticipated to expand due to the rising demand for gene therapy. Gene therapy is a medical approach focused on altering or replacing faulty genes to address or prevent various diseases. Its increasing appeal stems from its capability to treat genetic conditions, cancer, and rare diseases by targeting their underlying genetic origins, which in turn fuels substantial investments and progress in biotechnology. For fatty acid oxidation disorders, gene therapy works by introducing functional genes to rectify metabolic shortcomings, thereby restoring enzymatic activity, boosting energy production, and averting disease complications. As an illustration, in 2024, the American Society of Gene & Cell Therapy (ASGCT), a US-based, nonprofit, professional medical and scientific organization, indicated that the worldwide pipeline for gene, cell, and RNA therapies grew from 3,483 in Q4 2022 to 3,951 in Q4 2023, reaching 4,238 in Q4 2024. Consequently, the escalating demand for gene therapy is propelling the expansion of the fatty acid oxidation disorders (FAODs) market.
What Segment Categories Shape The Fatty Acid Oxidation Disorders (FAODs) Market Segment Landscape?
The fatty acid oxidation disorders (faods) market covered in this report is segmented –
1) By Type: Long Chain, Short Chain
2) By Drug Type: Levocarnitine, Dextrose, Riboflavin, Other Drug Types
3) By Route of Administration: Oral, Intravenous
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Stores
5) By End User: Hospitals, Clinics, Pharmaceutical Companies
Subsegments:
1) By Long Chain: Very Long-Chain Acyl-CoA Dehydrogenase Deficiency (VLCAD), Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency (LCHAD), Trifunctional Protein Deficiency (TFP), Carnitine Palmitoyltransferase II Deficiency (CPT II)
2) By Short Chain: Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD), Short-Chain Acyl-CoA Dehydrogenase Deficiency (SCAD), Carnitine Uptake Defect (CUD)
Which Trends Are Influencing Demand In The Fatty Acid Oxidation Disorders (FAODs) Market?
Leading companies in the fatty acid oxidation disorders (FAODs) market are prioritizing the development of innovative solutions, such as peroxisome proliferator-activated receptor delta (PPARd) agonists, to improve metabolic regulation and treatment outcomes for FAODs patients. A PPARd agonist is a substance that activates the PPARd receptor, which plays a role in controlling lipid metabolism, inflammation, and energy balance, potentially offering therapeutic benefits for metabolic disorders and cardiovascular diseases. For example, in January 2023, Reneo Pharmaceuticals Inc., a US-based clinical-stage pharmaceutical company, received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its investigational drug, Mavodelpar (REN001), which targets long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, a genotype linked to long-chain fatty acid oxidation disorder (LC-FAOD). Mavodelpar aims to activate PPARd, thereby enhancing mitochondrial function, improving energy metabolism, and reducing symptoms associated with LC-FAOD.
Who Are The Companies Operating Across The Fatty Acid Oxidation Disorders (FAODs) Market Value Chain?
Major companies operating in the fatty acid oxidation disorders (faods) market are Takeda Pharmaceutical Company Limited, Ultragenyx Pharmaceutical Inc, Sanofi SA, Novo Nordisk A S, Pfizer Inc, Merck & Co Inc, AstraZeneca PLC, Amgen Inc, AbbVie Inc, BioMarin Pharmaceutical Inc, PTC Therapeutics Inc, Horizon Therapeutics PLC, Recordati Rare Diseases SpA, Orphazyme A S, Mitsubishi Tanabe Pharma Corporation, Alexion Pharmaceuticals Inc (AstraZeneca Rare Disease), REGENXBIO Inc, Avrobio Inc, Homology Medicines Inc, Abeona Therapeutics Inc
Get The Full Fatty Acid Oxidation Disorders (FAODs) Market Report:
Which Region Is The Leading Market For The Fatty Acid Oxidation Disorders (FAODs) Market?
Asia-Pacific was the largest region in the fatty acid oxidation disorders (FAODs) market in 2025. The regions covered in the fatty acid oxidation disorders (faods) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Fatty Acid Oxidation Disorders (FAODs) Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Fatty Acid Oxidation Disorders (FAODs) Market 2026, By The Business Research Company
Palm Kernel Fatty Acids Market Report 2026
https://www.thebusinessresearchcompany.com/report/palm-kernel-fatty-acids-global-market-report
Tall Oil Fatty Acid Market Report 2026
https://www.thebusinessresearchcompany.com/report/tall-oil-fatty-acid-global-market-report
Fats And Oils Market Report 2026
https://www.thebusinessresearchcompany.com/report/fats-and-oils-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
